Safety Triggers

Retatrutide

Known safety concerns, contraindications, and risk factors.

Personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN 2

Strictly contraindicated based on rodent C-cell hyperplasia data and GLP-1 receptor class warnings.

Avoid

History of pancreatitis or severe gallbladder disease

Generally excluded from clinical trials due to risk of acute pancreatitis.

Avoid

Severe pre-existing gastroparesis

Major risk factor as the peptide further slows gastric emptying.

Avoid

Concurrent use of insulin or sulfonylureas without dosage adjustment

The most significant drug interaction risk: hypoglycemia (dangerously low blood sugar).

Warning

Pregnant or breastfeeding women

Safety has not been established for pregnant or breastfeeding women.

Avoid

Type 1 Diabetes

Retatrutide is not an insulin replacement and is not indicated for Type 1 diabetes.

Avoid

Retatrutide is investigational and NOT FDA-approved as of 2026

Absolutely contraindicated with personal or family history of MTC or MEN 2

Acute pancreatitis reported in ~2% at 12 mg — monitor lipase/amylase

Dysesthesia (tingling/burning) in 20.9% at 12 mg — unique to this compound

HR increase of 5-10 bpm expected — monitor cardiovascular markers

Severe GI distress in >50% at high doses — follow strict titration schedule

Mandatory protein intake 1.2-1.5g/kg and resistance training to prevent sarcopenia

Grey market sources carry severe contamination risk — TFA, heavy metals, endotoxins

Drug interaction: hypoglycemia risk with concurrent insulin or sulfonylureas

AKI risk secondary to dehydration from GI symptoms — maintain hydration

Safety Triggers — Retatrutide | pin.board